Update: This webinar has been rescheduled to Tuesday, November 10, 2020.
Assessment of Needs
Opioid use disorder is a growing crisis among people in the US, and people with HIV (PWH) are particularly affected. This talk will summarize the current knowledge in the field (eg, epidemiology, neurobiology) and will present a real-world, stepwise approach to opioid use disorder among PWH or hepatitis that can be implemented in any clinical setting. This talk will include both nonpharmacological interventions (eg, brief motivational interventions), as well as pharmacological interventions (eg, buprenorphine).
Upon completion of this webinar, learners will be able to:
- Describe the basic methods of screening for and addressing opioid use disorder in people with HIV
- Explain how to initiate treatment for opioid use disorders
- Implement the basic principles of caring for HIV and HCV in people with opioid use disorder
Note: The IAS–USA acknowledges the importance of delivering the same high-quality education and resources to our audiences despite the challenging times we are experiencing due to the COVID-19 pandemic. In response, the implementation of a nominal fee to process the claim of CME and CE credits for webinars has been postponed.
Who Should Attend
This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.
This activity is also relevant for registered nurses, PharmDs, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Monday, November 2, 2020, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is eligible for ANCC credit; see the final CNE activity announcement for specific details.
This activity is eligible for ACPE credit; see the final CPE activity announcement for specific details.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Merck & Co, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.